ActHIB
STN: 103935
Proper Name: Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)
Tradename: ActHIB
Manufacturer: Sanofi Pasteur Inc.
Indication:
- ActHIB is a vaccine indicated for the prevention of invasive disease caused by Haemophilus influenzae type b. ActHIB vaccine is approved for use as a four dose series in infants and children 2 months through 5 years of age.
Product Information
Supporting Documents
- October 13, 2022 Approval Letter - ActHIB
- July 27, 2022 Approval Letter - ActHIB
- May 24, 2019 Approval Letter - ActHIB
- Supporting Documents older than three years - ActHIB